HDAC1 and gastric cancer: Therefore, expression of HDAC1 and -2 are not helpful to predict response to treatment or survival in gastric cancer patients treated with neoadjuvant therapy, but HDAC1 expression may be beneficial for risk stratification in patients with disease that responds to therapy (163).